trending Market Intelligence /marketintelligence/en/news-insights/trending/hvpseb_eoprwnaxuauxqda2 content esgSubNav
In This List

Regenxbio plans common stock offering

Blog

Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Regenxbio plans common stock offering

REGENXBIO Inc., a gene therapy company, plans to sell $175 million of its common stock in an underwritten public offering.

The Rockville, Md.-based company said underwriters will have an option to buy up to an additional 15% of the common shares sold under the offer.

Morgan Stanley, Bank of America Merrill Lynch and Barclays are acting as joint book-running managers. Raymond James is acting as co-manager of the offering.

Regenxbio uses its NAV technology platform, an adeno-associated virus gene delivery platform, to engineer product candidates for treatment of retinal, metabolic and neurodegenerative diseases.